Risk-based classification of hypertension and the role of combination therapy.
The recognition of a continuous relationship between elevated blood pressure (BP) and cardiovascular risk has influenced national and international guidelines for the classification, prevention, and management of hypertension. The most recent report (2003) of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure uses BP thresholds to define categories of normal, prehypertension, and hypertension. A new definition proposed by the Hypertension Writing Group in 2005 offers an approach to diagnosis and management based on global or total risk. Thus, even in the absence of sustained elevations in BP, patients may have a moderate to high risk of vascular events due to the presence of additional cardiovascular risk factors, disease markers, and target organ damage. The 2007 European guidelines continue to classify hypertension based on cutoffs while also placing emphasis on multivariate formulations for cardiovascular risk assessment and goals of therapy. All 3 sets of guidelines acknowledge the necessity of using > or =2 antihypertensive agents to attain BP goals in many patients.
Weir
Matthew R
MR
Division of Nephrology, University of Maryland School of Medicine, Baltimore, MD 21202, USA. mweir@medicine.maryland.edu
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000145:classification / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004232:Diuretics / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D017408:Guidelines as Topic; D006801:Humans; D006973:Hypertension / Q000145:classification* / Q000150:complications / Q000188:drug therapy; D018570:Risk Assessment; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics